Rituximab maintenance halves MCL death risk after ASCTSeptember 27, 2017Lymphoma & Plasma Cell Disorders
FDA grants accelerated approval to copanlisib for relapsed follicular lymphomaSeptember 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65September 20, 2017Lymphoma & Plasma Cell Disorders
In Hodgkin lymphoma, HAPLO transplant outcomes match those of conventional transplantsSeptember 15, 2017Lymphoma & Plasma Cell Disorders
Most daratumumab infusion reactions occur in first infusionSeptember 14, 2017Lymphoma & Plasma Cell Disorders
KW-2478 examined as novel add-on therapy for myelomaSeptember 13, 2017Lymphoma & Plasma Cell Disorders
Biosimilar matches rituximab in large follicular lymphoma trialSeptember 12, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA alert: pembrolizumab ups mortality risk in multiple myelomaAugust 31, 2017Lymphoma & Plasma Cell Disorders
FDA grants Priority Review to Gazyva for follicular lymphomaAugust 29, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Obinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCLAugust 17, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Vitamin D level linked to post-alloSCT relapse risk in myelomaAugust 15, 2017Lymphoma & Plasma Cell Disorders
Crizotinib shows responses in pediatric ALCL and IMTAugust 15, 2017Lymphoma & Plasma Cell DisordersPediatrics
Lenalidomide maintenance boosts survival in de novo myeloma after ASCTAugust 15, 2017Lymphoma & Plasma Cell Disorders
Solid organ transplantation contributes significantly to incidence of NHL among children and adolescentsAugust 3, 2017Lymphoma & Plasma Cell DisordersPediatricsPatient & Survivor Care
FDA grants priority review of acalabrutinib for second-line treatment of MCLAugust 2, 2017Lymphoma & Plasma Cell Disorders
